Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome

Circulation

Volumn 102, Issue 8, 2000, Pages 921-925

  Abriel, H ^a   Wehrens, X H T ^a   Benhorin, J ^b   Kerem, B ^c   Kass, R S ^a  

^a Columbia University ^*  (United States)

^b BIKUR CHOLIM HOSPITAL   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiarrhythmia agents; Electrophysiology; Genes; Ion channels; Pharmacology; Sodium

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; ION CHANNEL; LIDOCAINE; SODIUM CHANNEL;

ARTICLE; DRUG EFFECT; GENE MUTATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HUMAN CELL; LONG QT SYNDROME; PATCH CLAMP; PRIORITY JOURNAL; QT INTERVAL;

EID: 0034702931     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.8.921     Document Type: Article

References (31)

1. The long QT syndrome: Prospective longitudinal study of 328 families
2. The long Q-T syndrome
3. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
4. Molecular mechanism for an inherited cardiac arrhythmia
5. + channel mutations in the congenital long QT syndrome
6. + channel
7. 1-subunits
8. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel
9. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia
10. Identification of a new SCN5A mutation associated with the long QT syndrome
11. + channel α-subunit: A computational analysis
12. Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction
13. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels
14. + channels
15. Genetically defined therapy of inherited long-QT syndrome: Correction of abnormal repolarization by potassium
16. + channel linked long-QT syndrome
17. + channel blockade, β-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome
18. Pharmacological targeting of long QT mutant sodium
19. + channels
20. Preferential block of late sodium current in the LQT3 ΔKPQ mutant by the class I(C) antiarrhythmic flecainide
21. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome
22. + channel blockade and to increases in heart rate: Implications for gene-specific therapy
23. Gene-specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene
24. Effects of flecainide in patients with a new SCN5A mutation: Mutation-specific therapy for long-QT syndrome?
25. + channels
26. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches
27. Antiarrhythmic agents
28. Lidocaine block of cardiac sodium channels
29. Interactions of flecainide with guinea pig cardiac sodium channels: Importance of activation unblocking to the voltage dependence of recovery
30. Molecular properties of sodium and calcium channels
31. + channel mutation causing both long-QT and Brugada Syndromes